Edition:
United Kingdom

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

18.65USD
25 Sep 2018
Change (% chg)

$-0.10 (-0.53%)
Prev Close
$18.75
Open
$18.75
Day's High
$19.10
Day's Low
$18.60
Volume
29,976
Avg. Vol
198,205
52-wk High
$36.25
52-wk Low
$15.65

Chart for

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $1,189.59
Shares Outstanding(Mil.): 46.65
Dividend: --
Yield (%): --

Financials

  ACOR.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.94 -- --
ROI: -3.56 1.79 14.61
ROE: -6.31 3.28 16.33

U.S. appeals court invalidates Acorda patents on MS drug

A U.S. appeals court on Monday invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door to generic competition for the company's flagship product.

10 Sep 2018

UPDATE 1-U.S. appeals court invalidates Acorda patents on MS drug

Sept 10 A U.S. appeals court on Monday invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door to generic competition for the company's flagship product.

10 Sep 2018

UPDATE 2-Acorda loses bid for U.S. court order halting generic Ampyra sales

July 25 A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

25 Jul 2018

Acorda loses bid for U.S. court order halting generic Ampyra sales

A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

25 Jul 2018

BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14

* ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR FIRST QUARTER 2018

02 May 2018

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

19 Apr 2018

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

02 Apr 2018

BRIEF-Acorda Files Marketing Authorization Application For Inbrija

* ACORDA FILES MARKETING AUTHORIZATION APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

26 Mar 2018

Earnings vs. Estimates